skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More


Show More

Show More

2 Total results for product and free and sample content found


Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

By Emily Hayes 27 Nov 2020

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Topic Obesity Clinical Trials

Datamonitor Healthcare

The majority of overweight and obese patients do not receive pharmacotherapy

03 Nov 2016

The US obesity market is expected to increase in value from $533m in 2016 to $1.2bn in 2026, at a compound annual growth rate of 8.0%. Growth will be driven by increased use of branded pharmacological therapies to treat obesity, as well as the rising incidence of the disease.

Topic Obesity Research Wire

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: